Literature DB >> 18554279

Isolated growth hormone deficiency type II caused by a point mutation that alters both splice site strength and splicing enhancer function.

N Shariat1, C D Holladay, R K Cleary, J A Phillips, J G Patton.   

Abstract

A heterozygous single base mutation in the human growth hormone (GH) gene (GH-1) was identified in a family presenting with isolated GH deficiency type II (IGHD II). Affected individuals have a guanine to adenine transition at the first nucleotide of exon 3 (E3+1 G-->A) that results in exon skipping and production of a dominant-negative 17.5-kDa isoform. We show that the mechanistic basis for exon skipping is due to the unique position of this mutation because it weakens the 3' splice site and simultaneously disrupts a splicing enhancer located within the first seven bases of exon 3. A G-->T mutation at this same position not only affects splicing but also results in a premature stop codon for those transcripts that include exon 3. Thus, mutations that alter the first nucleotide of exon 3 illustrate the various mechanisms by which changes in sequence can cause disease: splice site selection, splicing enhancer function, messenger RNA decay, missense mutations, and nonsense mutations. For IGHD II, only exon skipping leads to production of the dominant-negative isoform, with increasing skipping correlating with increasing disease severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18554279      PMCID: PMC4445398          DOI: 10.1111/j.1399-0004.2008.01042.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  32 in total

Review 1.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics.

Authors:  Lynne E Maquat
Journal:  Nat Rev Mol Cell Biol       Date:  2004-02       Impact factor: 94.444

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.

Authors:  Joy D Cogan; Michael W Pauciulo; Amy P Batchman; Melissa A Prince; Ivan M Robbins; Lora K Hedges; Krista C Stanton; Lisa A Wheeler; John A Phillips; James E Loyd; William C Nichols
Journal:  Am J Respir Crit Care Med       Date:  2006-05-25       Impact factor: 21.405

Review 4.  Long-term experience with GH replacement therapy: efficacy and safety.

Authors:  John P Monson
Journal:  Eur J Endocrinol       Date:  2003-04       Impact factor: 6.664

5.  Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.

Authors:  Joy D Cogan; Cindy L Vnencak-Jones; John A Phillips; Kirk B Lane; Lisa A Wheeler; Ivan M Robbins; Gladys Garrison; Lora K Hedges; James E Loyd
Journal:  Genet Med       Date:  2005-03       Impact factor: 8.822

6.  Autosomal dominant growth hormone (GH) deficiency type II: the Del32-71-GH deletion mutant suppresses secretion of wild-type GH.

Authors:  M S Lee; M P Wajnrajch; S S Kim; L P Plotnick; J Wang; J M Gertner; R L Leibel; P S Dannies
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

7.  Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II.

Authors:  Robin C C Ryther; Lindsay M McGuinness; John A Phillips; Chanda T Moseley; Charalambos B Magoulas; Iain C A F Robinson; James G Patton
Journal:  Hum Genet       Date:  2003-04-29       Impact factor: 4.132

8.  A splicing enhancer exhibits both constitutive and regulated activities.

Authors:  M Tian; T Maniatis
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

9.  Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature.

Authors:  David S Millar; Mark D Lewis; Martin Horan; Vicky Newsway; Tammy E Easter; John W Gregory; Linda Fryklund; Martin Norin; Elizabeth C Crowne; Sally J Davies; Phillip Edwards; Jeremy Kirk; Kim Waldron; Patricia J Smith; John A Phillips; Maurice F Scanlon; Michael Krawczak; David N Cooper; Annie M Procter
Journal:  Hum Mutat       Date:  2003-04       Impact factor: 4.878

10.  GH1 splicing is regulated by multiple enhancers whose mutation produces a dominant-negative GH isoform that can be degraded by allele-specific small interfering RNA (siRNA).

Authors:  Robin C C Ryther; Alex S Flynt; Bryan D Harris; John A Phillips; James G Patton
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  8 in total

1.  Pharmacologic correction of dominant-negative GH1 deficiency causing mutations.

Authors:  Justin S Poling; John A Phillips; Joy D Cogan; Rizwan Hamid
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

Review 2.  Phenotype-genotype correlations in congenital isolated growth hormone deficiency (IGHD).

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Indian J Pediatr       Date:  2011-12-03       Impact factor: 1.967

Review 3.  Genetic causes and treatment of isolated growth hormone deficiency-an update.

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

4.  A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II.

Authors:  Rizwan Hamid; John A Phillips; Cindy Holladay; Joy D Cogan; Eric D Austin; Philippe F Backeljauw; Sharon H Travers; James G Patton
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

5.  Exon first nucleotide mutations in splicing: evaluation of in silico prediction tools.

Authors:  Lucie Grodecká; Pavla Lockerová; Barbora Ravčuková; Emanuele Buratti; Francisco E Baralle; Ladislav Dušek; Tomáš Freiberger
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

6.  Next generation sequencing panel based on single molecule molecular inversion probes for detecting genetic variants in children with hypopituitarism.

Authors:  María I Pérez Millán; Sebastian A Vishnopolska; Alexandre Z Daly; Juan P Bustamante; Adriana Seilicovich; Ignacio Bergadá; Débora Braslavsky; Ana C Keselman; Rosemary M Lemons; Amanda H Mortensen; Marcelo A Marti; Sally A Camper; Jacob O Kitzman
Journal:  Mol Genet Genomic Med       Date:  2018-05-08       Impact factor: 2.183

7.  Splicing Enhancers at Intron-Exon Borders Participate in Acceptor Splice Sites Recognition.

Authors:  Tatiana Kováčová; Přemysl Souček; Pavla Hujová; Tomáš Freiberger; Lucie Grodecká
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

8.  High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency.

Authors:  Peter Gergics; Cathy Smith; Hironori Bando; Alexander A L Jorge; Denise Rockstroh-Lippold; Sebastian A Vishnopolska; Frederic Castinetti; Mariam Maksutova; Luciani Renata Silveira Carvalho; Julia Hoppmann; Julián Martínez Mayer; Frédérique Albarel; Debora Braslavsky; Ana Keselman; Ignacio Bergadá; Marcelo A Martí; Alexandru Saveanu; Anne Barlier; Rami Abou Jamra; Michael H Guo; Andrew Dauber; Marilena Nakaguma; Berenice B Mendonca; Sajini N Jayakody; A Bilge Ozel; Qing Fang; Qianyi Ma; Jun Z Li; Thierry Brue; María Ines Pérez Millán; Ivo J P Arnhold; Roland Pfaeffle; Jacob O Kitzman; Sally A Camper
Journal:  Am J Hum Genet       Date:  2021-07-15       Impact factor: 11.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.